| Filed On | Filing |
|---|---|
| 21 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
This AMENDMENT NO. 2 TO AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER, dated as of September 15, 2026 (this “Amendment No. 2”), is entered into by and between Insight Molecular Diagnostics Inc. (formerly known as Oncocyte Corporation... |
| 10 Aug 2026 | 10-Q |
| 10 Aug 2026 | 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more |
| 24 Jul 2026 | S-8 |
| 06 Jul 2026 |
Form 4: Silverman Lou, Director
Gave up 7,700 shares to cover exercise price or tax ($43.8K) |
| 06 Jul 2026 |
Form 4: Last Andrew J., Director
Gave up 7,700 shares to cover exercise price or tax ($43.8K) |
| 06 Jul 2026 |
Form 4: Arno Andrew, Director
Gave up 12,100 shares to cover exercise price or tax ($68.8K) |
| 17 Jun 2026 | 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders |
| 15 Jun 2026 |
Form 4: Silverman Lou, Director
Received 26,943 shares as a grant or award |
| 15 Jun 2026 |
Form 4: Last Andrew J., Director
Received 26,943 shares as a grant or award |
| 15 Jun 2026 |
Form 4: Arno Andrew, Director
Received 32,331 shares as a grant or award |
| 13 May 2026 | 10-Q |
| 13 May 2026 |
8-K/A: Other Events
On February 20, 2026, iMDx announced that it had entered into a Specimen Collection Agreement with Quest Diagnostics for certain specimen collection-related services related to the Company’s GraftAssureCoreTM test, a blood test designed ... |
| 13 May 2026 | 8-K: Results of Operations and Financial Condition |
| 30 Apr 2026 | ARS |
| 30 Apr 2026 | DEFA14A |
| 30 Apr 2026 |
Proxy statement: annual meeting on June 11, 2026
CEO pay $2.6M, up 230% · say-on-pay vote |
| 30 Apr 2026 | 8-K: Other Events |
| 27 Apr 2026 | SCHEDULE 13D/A |
| 27 Apr 2026 |
Form 4: Broadwood PARTNERS, L.p., 10% owner and 2 others
Bought 280,381 shares · Bought 38,880 shares · Bought 250,923 shares |
Loading...
